Prevalence of statin and beta-blocker use by clinical presentation

Slides:

Advertisements

Similar presentations

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Advertisements

British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.

Atherosclerosis Part 1 Atherosclerosis The general term for hardening of the arteries The most prevalent form of atherosclerosis is characterized by the.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

Cardiovascular disease in a large cohort of depressed and/or anxious patients Results of the Netherlands Study of Depression and Anxiety N Vogelzangs 1,

The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Wayne Rosamond, et al. Circulation 2007;115; e69-e171.

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

New Guidelines for Myocardial Ischemia Management.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Contemporary Management of Myocardial Ischemia

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 5/29/2016 From: Statins and Cognitive Function: A Systematic Review Ann Intern Med. 2013;159(10): doi: /

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

An analysis of 22,672 patients from the CLARIFY registry

ALICE-PROTECT Study Yields Online Risk Prediction Tool in Diabetic Nephropathy From ESH 2016 | LB 1: Jean-Pierre Fauvel, MD CHU Lyon, Hôpital E Herriot,

What should the Systolic BP treatment goal be in patients with CKD?

Health and Human Services National Heart, Lung, and Blood Institute

The Intermountain heart collaborative study

From: Statins and Cognitive FunctionA Systematic Review

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Copyright © 2007 American Medical Association. All rights reserved.

Gender based differences in the presentation, treatment and outcome of Acute Coronary Syndrome patients : insights from the Himachal Pradesh ACS-registry.

ELIGIBILITY: MRC/BHF Heart Protection Study

Relationship of Physical Activity and Body Mass Index to the Risk of Hypertension: A Prospective Study in Finland by Gang Hu, Noël C. Barengo, Jaakko Tuomilehto,

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’

Adjusted mortality risk

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Creatinine clearance (mL/min) n All-cause mortality (%)

Section I: Clinical and epidemiological correlates of erectile dysfunction and cardiovascular disease Prevalence of sexual dysfunction in US adults Content.

Recurrent Angina: New Tools for an Old Problem

Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data by Masao Iwagami, Ben Caplin,

Volume 93, Issue 4, Pages (April 2018)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Cardiovascular Disease and CKD: Core Curriculum 2010

Dileep Raman et al. JACEP 2017;3:

Relative risk of hypertension by quintiles of lipids (mg/dL)

Preventive Angioplasty in Myocardial Infarction Trial

Volume 145, Issue 1, Pages (January 2014)

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data by Masao Iwagami, Ben Caplin,

Factors independently associated with odds of fractures

Risk for BMI outcome (%)

Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome Jonas Faxén, Hong Xu,

Baseline Characteristics According to Sex

Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.

Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Internal Medicine Workshop Series Laos September /October 2009

Associations between type of MI and incident HF

MRRs and EMRRs for women with ACS

A: Mean wall motion score index (95% CI) in patients with first myocardial infarction segregated by Hp type. A: Mean wall motion score index (95% CI) in.

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Low/moderate intensity statins High intensity statins

Adjusted prevalence of CHD, atrial fibrillation, and stroke by sex and ethnic group. Numbers for sex are adjusted for age and clustering within practices.

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.

Low/moderate intensity statins High intensity statins

Adjusted associations between hypertensive disorder of pregnancy subtypes and MI, heart failure and stroke. Adjusted associations between hypertensive.

Adjusted ORs of increasing severity of heartburn at follow-up in reference to baseline from model adjusted for BMI category, CVD history, BDI score >11,

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Presentation transcript:

Prevalence of statin and beta-blocker use by clinical presentation Treatment Acute MI, n=916* Stable angina, n=468† p Statin (%) 19.3 40.4 <0.001 Beta blocker (%) 19.0 47.7 *Men aged 45–75 and women aged 55–75 years †Men and women aged 18–75 Go AS et al. Ann Intern Med 2006; 144:229-238.

Adjusted risk of presentation with acute MI vs stable angina by treatment and history Parameter HR (95% OR) Recent statin use 0.45 (0.32–0.62) Recent beta blocker use 0.26 (0.19–0.35) Recent CCB use 1.62 (1.01–2.59) Prior hypertension 1.92 (1.35–2.73) Prior diabetes 1.69 (1.15–2.49) Male sex 1.89 (1.37–2.56) Former cigarette smoking 1.35 (1.01–1.79) Current cigarette smoking 1.72 (0.99–2.97) CCB=calcium-channel blocker Model adjusted for use of any studied medication classes; age; sex; ethnicity; parental CAD history; smoking status; previous alcohol use; physical activity level; previous stroke, peripheral artery disease, hypertension, or HF hospitalization; diabetes; dementia; depression; and other factors Go AS et al. Ann Intern Med 2006; 144:229-238.